【Leading Radioactive and Live Imaging Technology】The platform integrates 36 types of nuclide qualifications (3H/14C/125I/89Zr) and class B radiation sites, alongside QWBA, PET/SPECT live imaging technology, enabling high-sensitivity detection and clinical dose transformation for ADCs and gene therapy drugs. This integration fills the gap in complex drug analysis within China.
【Multidimensional Metabolic Research Capability】The platform covers in vitro metabolic models such as human liver microsomes, recombinant enzymes, and hepatocytes. Coupled with rodent to non-human primate studies, it accurately analyzes metabolic pathways and addresses the unique pharmacokinetic characteristics of nucleotide drugs, providing effective service solutions for emerging R&D directions, such as small nucleic acid drugs.
【Full-Category Drug Service and Efficient Transformation Ability】With nearly 100 IND projects completed annually, InnoStar supports a diverse range of drugs, including small molecules, antibody drugs (ADC/bispecific antibodies), gene therapies (CAR-T/AAV), nucleic acid drugs, and radiopharmaceuticals. The platform supports the full lifecycle from IND to NDA/BLA, enabling efficient and reliable transformation of research into clinical application.